Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)
A Randomized, Double-Blind, Dose-Escalation Study Evaluating Pharmacokinetics and Safety of Anthrax Immune Globulin Intravenous (AIGIV)
Sponsor: Emergent BioSolutions
A PHASE1/PHASE2 clinical study on Anthrax, this trial is completed. The trial is conducted by Emergent BioSolutions and has accumulated 11 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Apr 2024 [monthly]
Completed PHASE1_PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 6 earlier versions
-
Aug 2018 — Aug 2019 [monthly]
Completed PHASE1_PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE1_PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Mar 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Feb 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Emergent BioSolutions
- National Institutes of Health (NIH)
For direct contact, visit the study record on ClinicalTrials.gov .